Neuromyelitis optica: Concept, immunology and treatment

Journal of Clinical Neuroscience

Volumn 21, Issue 1, 2014, Pages 12-21

  Uzawa, Akiyuki ^a   Mori, Masahiro ^a   Kuwabara, Satoshi ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

Aquaporin 4 antibody; Astrocyte; Blood brain barrier; Glial fibrillary acidic protein; Interleukin 6; Neuromyelitis optica

Indexed keywords

AQUAPORIN 4 ANTIBODY; AQUAPORUMAB; AZATHIOPRINE; BETA INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ECULIZUMAB; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 6; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; SIVELESTAT; TOCILIZUMAB; UNCLASSIFIED DRUG;

ANTIBODY DETECTION; BLOOD BRAIN BARRIER; BRAIN DAMAGE; CEREBROSPINAL FLUID ANALYSIS; CEREBROSPINAL FLUID CYTOLOGY; CLINICAL FEATURE; DRUG MEGADOSE; GEOGRAPHIC DISTRIBUTION; HUMAN; LOW DRUG DOSE; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NEUROIMAGING; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NERVE LESION; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; REVIEW; SEROLOGY; SJOEGREN SYNDROME; SPINAL CORD LESION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH1 TH2 BALANCE;

AQUAPORIN-4 ANTIBODY; ASTROCYTE; BLOOD-BRAIN BARRIER; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN-6; NEUROMYELITIS OPTICA;

HUMANS; NEUROMYELITIS OPTICA;

EID: 84890565442     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2012.12.022     Document Type: Review

References (77)

1. D.M. Wingerchuk, V.A. Lennon, and S.J. Pittock Revised diagnostic criteria for neuromyelitis optica Neurology 66 2006 1485 1489
2. E. Devic My élite subaiguë compliquée de névrite optique Bull Med (Paris) 8 1894 1033 1034
3. V.A. Lennon, D.M. Wingerchuk, and T.J. Kryzer A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis Lancet 364 2004 2106 2112
4. V.A. Lennon, T.J. Kryzer, and S.J. Pittock IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel J Exp Med 202 2005 473 477
5. K. Fujihara Neuromyelitis optica and astrocytic damage in its pathogenesis J Neurol Sci 306 2011 183 187
6. A. Uzawa, M. Mori, and M. Muto When is neuromyelitis optica diagnosed after disease onset? J Neurol 259 2012 1600 1605
7. N. Asgari, S.T. Lillevang, and H.P. Skejoe A population-based study of neuromyelitis optica in Caucasians Neurology 76 2011 1589 1595
8. N. Collongues, R. Marignier, and H. Zéphir Neuromyelitis optica in France: a multicenter study of 125 patients Neurology 74 2010 736 742
9. P. Cabre, A. González-Quevedo, and M. Bonnan Relapsing neuromyelitis optica: long term history and clinical predictors of death J Neurol Neurosurg Psychiatry 80 2009 1162 1164
10. A. Nagaishi, M. Takagi, and A. Umemura Clinical features of neuromyelitis optica in a large Japanese cohort: comparison between phenotypes J Neurol Neurosurg Psychiatry 82 2011 1360 1364
11. A. Uzawa, M. Mori, and M. Ito Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis J Neurol 256 2009 2082 2084
12. A. Uzawa, M. Mori, and K. Arai Cytokine and chemokine profiles in neuromyelitis optica: significance of interleukin-6 Mult Scler 16 2010 1443 1452
13. A. Uzawa, M. Mori, and S. Hayakawa Expression of chemokine receptors on peripheral blood lymphocytes in multiple sclerosis and neuromyelitis optica BMC Neurol 10 2010 113
14. K. Okada, T. Matsushita, and J. Kira B-cell activating factor of the TNF family is upregulated in neuromyelitis optica Neurology 74 2010 177 178
15. T. Misu, K. Fujihara, and A. Kakita Loss of aquaporin-4 in lesions of neuromyelitis optica: distinction from multiple sclerosis Brain 130 2007 1224 1234
16. S.F. Roemer, J.E. Parisi, and V.A. Lennon Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis Brain 130 2007 1194 1205
17. A. Uzawa, M. Mori, and S. Hayakawa Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis Eur J Neurol 17 2010 672 676
18. S. Watanabe, T. Misu, and I. Miyazawa Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis Mult Scler 13 2007 968 974
19. C. Costanzi, M. Matiello, and C.F. Lucchinetti Azathioprine: tolerability, efficacy, and predictor of benefit in neuromyelitis optica Neurology 77 2011 659 666
20. A. Jacob, M. Matiello, and B.G. Weinshenker Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients Arch Neurol 66 2009 1128 1133
21. S.H. Kim, W. Kim, and M.S. Park Efficacy and safety of mithoxantrone in patients with highly relapsing neuromyelitis optica Arch Neurol 68 2011 473 479
22. S.H. Kim, W. Kim, and X.F. Li Repeated treatment with rituximab based on the assessment of peripheral circulating B cells in patients with relapsing neuromyeltis optica Arch Neurol 68 2011 1412 1420
23. T. Aoyama A case of acute myelitis and blindness J Tokyo Med Assoc 5 1891 827 830
24. T.C. Albutt On the ophthalmoscopic signs of spinal disease Lancet 95 1870 76 78
25. Gault F. De la neuromyélite optique aiguë. Lyon 1894 (thesis).
26. M.A. Mealy, D.M. Wingerchuk, and B.M. Greenberg Epidemiology of neuromyelitis optica in the United States: a multicenter analysis epidemiology of NMO Arch Neurol 69 2012 1176 1180
27. J.A. Cabrera-Gómez, J.F. Kurtzke, and A. González-Quevedo An epidemiological study of neuromyelitis optica in Cuba J Neurol 256 2009 35 44
28. J.F. Rivera, J.F. Kurtzke, and V.J. Booth Characteristics of Devic's disease (neuromyelitis optica) in Mexico J Neurol 255 2008 710 715
29. M. Cossburn, G. Tackley, and K. Baker The prevalence of neuromyelitis optica in South East Wales Eur J Neurol 19 2012 655 659
30. Y. Long, W. Qiu, and X. Hu Anti-aquaporin-4 antibody in Chinese patients with central nervous system inflammatory demyelinating disorders Clin Neurol Neurosurg 114 2012 1131 1134
31. S. Siritho, I. Nakashima, and T. Takahashi AQP4 antibody-positive Thai cases: clinical features and diagnostic problems Neurology 77 2011 827 834
32. W. Kim, M.S. Park, and S.H. Lee Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity Mult Scler 16 2010 1229 1236
33. M. Muto, M. Mori, and Y. Sato Seasonality of multiple sclerosis and neuromyelitis optica exacerbations in Japan Mult Scler. 19 2013 378 379
34. D.W. Paty, J.J. Oger, and L.F. Kastrukoff MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT Neurology 38 1988 180 185
35. R. Takano, T. Misu, and T. Takahashi Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study Neurology 75 2010 208 216
36. T. Takahashi, K. Fujihara, and I. Nakashima Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre Brain 130 2007 1235 1243
37. F. Paul, S. Jarius, and O. Aktas Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica PLoS Med 4 2007 e133
38. S. Hayakawa, M. Mori, and A. Okuta Neuromyelitis optica and anti-aquaporin-4 antibodies measured by an enzyme-linked immunosorbent assay J Neuroimmunol 196 2008 181 187
39. P. Waters, and A. Vincent Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays Int MS J 15 2008 99 105
40. P.J. Waters, A. McKeon, and M.I. Leite Serologic diagnosis of NMO: a multicente comparison of aquaporin-4-IgG assays Neurology 78 2012 665 671
41. D.M. Wingerchuk, and B.G. Weinshenker Neuromyelitis optica: clinical predictors of a relapsing course and survival Neurology 60 2003 848 853
42. J. Kitley, M.I. Leite, and I. Nakashima Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan Brain 135 2012 1834 1849
43. A. Uzawa, M. Mori, and Y. Sato CSF interleukin-6 level predicts recovery from neuromyelitis optica relapse J Neurol Neurosurg Psychiatry 83 2012 339 340
44. W. Kim, S.H. Kim, and I. Nakashima Influence of pregnancy on neuromyelitis optica spectrum disorder Neurology 78 2012 1264 1267
45. N. Chihara, T. Aranami, and W. Sato Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica Proc Natl Acad Sci USA 108 2011 3701 3706
46. H.H. Wang, Y.Q. Dai, and W. Qiu Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse J Clin Neurosci 18 2011 1313 1317
47. M. Varrin-Doyer, C.M. Spencer, and U. Schulze-Topphoff Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter Ann Neurol 72 2012 53 64
48. Y. Li, H. Wang, and Y. Long Increased memory Th17 cells in patients with neuromyelitis optica and multiple sclerosis J Neuroimmunol 234 2011 155 160
49. A.I. Kaplin, D.M. Deshpande, and E. Scott IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis J Clin Invest 115 2005 2731 2741
50. H. Zhang, J.L. Bennett, and A.S. Verkman Ex vivo spinal cord slice model of neuromyelitis optica reveals novel immunopathogenic mechanisms Ann Neurol 70 2011 943 954
51. S. Jarius, D. Franciotta, and F. Paul Cerebrospinal fluid antibodies to aquaporin-4 in neuromyelitis optica and related disorders: frequency, origin, and diagnostic relevance J Neuroinflammation 7 2010 52
52. A. Uzawa, M. Mori, and S. Masuda Markedly elevated soluble intercellular adhesion molecule 1, soluble vascular cell adhesion molecule 1 levels, and blood-brain barrier breakdown in neuromyelitis optica Arch Neurol 68 2011 913 917
53. M. Bradl, T. Misu, and T. Takahashi Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo Ann Neurol 66 2009 630 643
54. S. Nishiyama, T. Ito, and T. Misu A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset Neurology 72 2009 1960 1961
55. M. Mori, N. Kawaguchi, and A. Uzawa Seroconversion of anti-aquaporin-4 antibody in NMO spectrum disorder: a case report J Neurol 259 2012 980 981
56. F. Shimizu, Y. Sano, and T. Takahashi Sera from neuromyelitis optica patients disrupt the blood-brain barrier J Neurol Neurosurg Psychiatry 83 2012 288 297
57. S.J. Pittock, V.A. Lennon, and J. de Seze Neuromyelitis optica and non organ-specific autoimmunity Arch Neurol 65 2008 78 83
58. A. Uzawa, M. Mori, and Y. Iwai Association of anti-aquaporin-4 antibody-positive neuromyelitis optica with myasthenia gravis J Neurol Sci 287 2009 105 107
59. M.I. Leite, E. Coutinho, and M. Lana-Peixoto Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients Neurology 78 2012 1601 1607
60. S. Ito, M. Mori, and T. Makino "Cloud-like enhancement" is a magnetic resonance imaging abnormality specific to neuromyelitis optica Ann Neurol 66 2009 425 428
61. S.J. Pittock, V.A. Lennon, and K. Krecke Brain abnormalities in neuromyelitis optica Arch Neurol 63 2006 390 396
62. S.J. Pittock, B.G. Weinshenker, and C.F. Lucchinetti Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression Arch Neurol 63 2006 964 968
63. T. Misu, K. Fujihara, and I. Nakashima Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica Neurology 65 2005 1479 1482
64. T. Baba, I. Nakashima, and T. Kanbayashi Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody J Neurol 256 2009 287 288
65. T. Makino, S. Ito, and M. Mori Diffuse and heterogeneous T2-hyperintense lesions in the splenium are characteristic of neuromyelitis optica Mult Scler 19 2012 308 315
66. M. Nakamura, T. Misu, and K. Fujihara Occurrence of acute large and edematous callosal lesions in neuromyelitis optica Mult Scler 15 2009 695 700
67. M. Nakamura, I. Miyazawa, and K. Fujihara Preferential spinal central gray matter involvement in neuromyelitis optica. An MRI study J Neurol 255 2008 163 170
68. S. Khanna, A. Sharma, and J. Huecker Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis J Neuroophthalmol 32 2012 216 220
69. R.T. Naismith, N.T. Tutlam, and J. Xu Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis Neurology 72 2009 1077 1082
70. S. Watanabe, I. Nakashima, and T. Misu Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica Mult Scler 13 2007 128 132
71. I. Kleiter, K. Hellwig, and A. Berthele Failure of natalizumab to prevent relapses in neuromyelitis optica Arch Neurol 69 2012 239 245
72. J.H. Min, B.J. Kim, and K.H. Lee Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder Mult Scler 18 2012 113 115
73. M.C. Papadopoulos, and A.S. Verkman Aquaporin 4 and neuromyelitis optica Lancet Neurol 11 2012 535 544
74. M. Araki, T. Aranami, and T. Matsuoka Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab Mod Rheumatol 2012 [Epub ahead of print]
75. L. Tradtrantip, H. Zhang, and S. Saadoun Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica Ann Neurol 71 2012 314 322
76. S. Saadoun, P. Waters, and C. MacDonald Neutrophil protease inhibition reduces neuromyelitis optica-immunoglobulin G-induced damage in mouse brain Ann Neurol 71 2012 323 333
77. MS-UK. < http://www.msrc.co.uk/index.cfm/fuseaction/show/pageid/2325 >; 2013 [accessed 15.02.13].